| Literature DB >> 35072394 |
Álvaro Rösler1, Gabriel Constantin1, Pedro Nectoux1, Bruno Sell Holz1, Estevan Letti1, Marcela Sales1, Fernanda Lucchese-Lobato2, Fernando Lucchese2,2.
Abstract
INTRODUCTION: Coronary artery bypass grafting (CABG) performed with and without cardiopulmonary bypass (CPB) support has been widely discussed in the literature. However, little is known about the outcomes of those techniques in Brazil. This study aims at exploring 30-day mortality and morbidity outcomes of on- and off-pump isolated CABG in a large sample from Southern Brazil.Entities:
Keywords: Cardiopulmonary Bypass; Logistic Model; Morbidity; Propensity Score; Reoperation, Myocardial Infarction
Mesh:
Year: 2022 PMID: 35072394 PMCID: PMC8973147 DOI: 10.21470/1678-9741-2021-0229
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Boxplot of the propensity scores of stratified paired study groups. CABG=coronary artery bypass grafting.
Baseline characteristics stratified by CPB support.
| Characteristics | Off-pump CABG (n=332) | On-pump CABG (n=332) | |
|---|---|---|---|
| Female gender | 98 (29.5%) | 108 (32.5%) | 0.402 |
| Age (years) | 62,7±9,8 | 62,3±8,6 | 0.568 |
| Hypertension | 276 (83.1%) | 270 (81.3%) | 0.542 |
| Diabetes | 128 (38.6%) | 138 (41.6%) | 0.428 |
| AMI | 109 (32.8%) | 109 (32.8%) | 1.000 |
| Renal impairment | 32 (9.6%) | 33 (9.9%) | 0.986 |
| Hemodialysis | 08 (2.4%) | 12 (3.6%) | 0.364 |
| Creatinine clearance | 75,1±27,2 | 77,3±29,9 | 0,333 |
| Smoking | 67 (20.2%) | 67 (20.2%) | 1.000 |
| COPD | 16 (4.8%) | 18 (5.4%) | 0.725 |
| Stroke | 25 (7.5%) | 24 (7.2%) | 0.882 |
| PVD | 14 (4.2%) | 13 (3.9%) | 0.844 |
| Atrial fibrillation | 08 (2.4%) | 07 (2.1%) | 0.794 |
| NYHA class III or IV HF | 63 (19%) | 61 (18.4%) | 0.842 |
| LV ejection fraction (%) | 61±12,0 | 60±12,7 | 0.199 |
| PASP (mmHg) | 29,2±6,6 | 29,3±7,6 | 0.957 |
| Frailty | 27 (8.1%) | 26 (7.8%) | 0.886 |
| Anemia | 99 (29.8%) | 97 (29.2%) | 0.865 |
| Instable angina | 24 (7.2%) | 31 (9.3%) | 0.324 |
| Previous CV surgery | 6 (1.8%) | 3 (0.9%) | 0.505 |
| Previous PCI | 82 (24.7%) | 62 (18.7%) | 0.060 |
| Urgency or emergency | 9 (2.7%) | 7 (2.1%) | 0.613 |
| EuroSCORE I | 3.34±4.24 | 3.26±3.34 | 0.805 |
| EuroSCORE II | 1.56±1.71 | 1.54±1.07 | 0.808 |
| STS score | 0.98±1.01 | 1.08±1.07 | 0.202 |
| Complete revascularization | 321 (96.7%) | 320 (96.4%) | 0.832 |
Fig. 2Thirty-day outcomes rates stratified by cardiopulmonary bypass support. AMI=acute myocardial infarction; MACCE=major adverse cardiovascular and cerebrovascular events.
Logistic regression analysis.
| Variables | B | SE | Wald | P | OR | 95% CI |
|---|---|---|---|---|---|---|
| Gender (male) | 1.539 | 0.623 | 6.109 | 0.013 | 4.659 | 1.375 - 15.787 |
| COPD (yes) | 1.775 | 0.766 | 5.378 | 0.020 | 5.903 | 1.316 - 26.469 |
| Atrial fibrillation (yes) | 2.257 | 0.942 | 5.738 | 0.017 | 9.550 | 1.507 - 60.509 |
| Anemia (yes) | 1.423 | 0.603 | 5.563 | 0.018 | 4.150 | 1.272 - 13.541 |
| CPB (yes) | 0.719 | 0.620 | 1.345 | 0.246 | 2.052 | 0.609 - 6.913 |
| Constant | -6.050 | 0.826 | 53.586 | < 0.001 | 0.002 | .... |
| Abbreviations, acronyms & symbols | |||
|---|---|---|---|
| AF | = Atrial fibrillation | LV | = Left ventricle |
| AMI | = Acute myocardial infarction | MACCE | = Major adverse cardiovascular and cerebrovascular events |
| B | = Unstandardized regression weight. | NYHA | = New York Heart Association |
| CABG | = Coronary artery bypass grafting | OR | = Odds ratio |
| CI | = Confidence interval | PASP | = Pulmonary artery systolic pressure |
| COPD | = Chronic obstructive pulmonary disease | PCI | = Percutaneous intervention |
| CPB | = Cardiopulmonary bypass | PVD | = Peripheral vascular disease |
| CV | = Cardiovascular | RCTs | = Randomized clinical trials |
| EuroSCORE | = European System for Cardiac Operative Risk Evaluation | SE | = Standard error |
| HF | = Heart failure | STS | = Society of Thoracic Surgeons |
| Authors' roles & responsibilities | |
|---|---|
| AR | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| GC | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| PN | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| BSH | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| EL | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| MS | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| FLL | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| FL | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |